- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04619420
En undersøgelse af JNJ-63733657 hos deltagere med tidlig Alzheimers sygdom (Autonomy)
En randomiseret, dobbeltblind, placebokontrolleret, parallelgruppe, multicenterundersøgelse for at vurdere effektiviteten og sikkerheden af JNJ-63733657, et anti-tau monoklonalt antistof, hos deltagere med tidlig Alzheimers sygdom
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
-
Adelaide, Australien, 5000
- Royal Adelaide Hospital
-
Box Hill, Australien, 3128
- Box Hill Hospital
-
Carlton, Australien, 3053
- Neuro Trials Victoria
-
Ivanhoe, Australien, 3079
- Austin Health
-
Malvern, Australien, 3144
- HammondCare Neurodegenerative Clinical Trials - VIC
-
Nedlands, Australien, 6009
- Australian Alzheimer's Research Foundation Incorporated
-
Parkville, Australien, 3050
- Royal Melbourne Hospital
-
-
-
-
-
Bruges, Belgien, 8000
- AZ St.-Jan Brugge-Oostende AV
-
Brussels, Belgien, 1200
- UCL Hopital Saint-Luc
-
Edegem, Belgien, 2650
- UZ Antwerpen
-
Ghent, Belgien, 9000
- Universitair Ziekenhuis Gent
-
Hasselt, Belgien, 3500
- Jessa Ziekenhuis
-
Jette, Belgien, 1090
- UZ Brussel
-
Leuven, Belgien, 3000
- UZ Leuven
-
Roeselare, Belgien, 8800
- Algemeen Ziekenhuis Delta
-
-
-
-
Ontario
-
London, Ontario, Canada, N6C 0A7
- Parkwood Institute
-
Peterborough, Ontario, Canada, K9H 2P4
- Kawartha Centre - Redefining Healthy Aging
-
Toronto, Ontario, Canada, M3B 257
- Toronto Memory Program (Neurology Research Inc.)
-
Toronto, Ontario, Canada, M5T 2S8
- UHN-Toronto Western Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 2B4
- McGill University
-
-
-
-
-
Bath, Det Forenede Kongerige, BA1 3NG
- Royal United Hospital
-
London, Det Forenede Kongerige, W6 8RF
- Charing Cross Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- University of Alabama Birmingham
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85013
- Dignity Health
-
-
California
-
Irvine, California, Forenede Stater, 92614
- Irvine Clinical Research
-
La Jolla, California, Forenede Stater, 92037
- University of California San Diego Medical Center
-
Los Angeles, California, Forenede Stater, 90095
- University of California - Los Angeles
-
Palo Alto, California, Forenede Stater, 94304
- Stanford University Medical Center
-
San Diego, California, Forenede Stater, 92103
- Pacific Research Network Prn
-
Santa Ana, California, Forenede Stater, 92705
- Syrentis Clinical Research
-
-
Connecticut
-
New Haven, Connecticut, Forenede Stater, 06510
- Yale University School Of Medicine
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20007
- Georgetown University Clinical Research Unit CRU
-
-
Florida
-
Atlantis, Florida, Forenede Stater, 33462
- JEM Research LLC
-
Delray Beach, Florida, Forenede Stater, 33445
- Brain Matters Research
-
Fort Myers, Florida, Forenede Stater, 33912
- Neuropsychiatric Research Center of SWFL
-
Jacksonville, Florida, Forenede Stater, 32256
- Clinical NeuroScience Solutions Inc
-
Jupiter, Florida, Forenede Stater, 33458
- Alphab Global Research
-
Maitland, Florida, Forenede Stater, 32751
- K2 Medical Research
-
Maitland, Florida, Forenede Stater, 32751
- Tandem Intermediate LLC
-
Merritt Island, Florida, Forenede Stater, 32952
- Merritt Island Medical Research, LLC
-
Miami, Florida, Forenede Stater, 33136
- University of Miami Miller School of Medicine
-
Miami, Florida, Forenede Stater, 33137
- Miami Jewish Health System
-
Naples, Florida, Forenede Stater, 34105
- Aqualane Clinical Research
-
Ocala, Florida, Forenede Stater, 34470
- Renstar Medical Research
-
Ocoee, Florida, Forenede Stater, 34761
- Sensible Healthcare
-
Tampa, Florida, Forenede Stater, 33609
- Axiom Clinical Research of Florida
-
Tampa, Florida, Forenede Stater, 33613
- Stedman Clinical Trials
-
Tampa, Florida, Forenede Stater, 33613
- University of South Florida - Health Byrd Alzheimer Institute
-
The Villages, Florida, Forenede Stater, 32162
- Charter Research
-
Viera, Florida, Forenede Stater, 32904
- ClinCloud Clinical Research
-
Wellington, Florida, Forenede Stater, 33414
- Alzheimers Research and Treatment Center
-
West Palm Beach, Florida, Forenede Stater, 33407
- Palm Beach Neurology and Premier Research Institute
-
Winter Park, Florida, Forenede Stater, 32789
- Conquest Research
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30329
- The Emory Clinic
-
Decatur, Georgia, Forenede Stater, 30030
- Sandhill Research
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60640
- Great Lakes Clinical Trials
-
Elk Grove Village, Illinois, Forenede Stater, 60007
- Alexian Brothers Medical Center - Neuroscience Research Institute
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, Forenede Stater, 02114
- Massachusetts General Hospital
-
Braintree, Massachusetts, Forenede Stater, 02184
- Anil Nair dba Alzheimer's Disease Center
-
-
Mississippi
-
Hattiesburg, Mississippi, Forenede Stater, 39401
- Hattiesburg Clinic
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School Of Medicine
-
-
New Jersey
-
Mount Arlington, New Jersey, Forenede Stater, 07856
- NeuroCognitive Institute
-
Princeton, New Jersey, Forenede Stater, 08540
- Princeton Medical Institute
-
Toms River, New Jersey, Forenede Stater, 08755
- Advanced Memory Research Institute of NJ
-
-
New York
-
Albany, New York, Forenede Stater, 12208
- Neurological Associates of Albany, PC
-
East Syracuse, New York, Forenede Stater, 13057
- Velocity Clinical Research
-
New York, New York, Forenede Stater, 10016
- New York University Medical Center
-
-
North Carolina
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest Health Sciences
-
-
Ohio
-
Cleveland, Ohio, Forenede Stater, 44195
- Cleveland Clinic Lou Revo Center for Brain Health
-
Columbus, Ohio, Forenede Stater, 43221
- Wexner Medical Center at the Ohio State University
-
-
Pennsylvania
-
Plymouth Meeting, Pennsylvania, Forenede Stater, 19462
- Keystone Clinical Studies LLC
-
-
Rhode Island
-
Providence, Rhode Island, Forenede Stater, 02906
- Brown University School of Medicine
-
-
Texas
-
Houston, Texas, Forenede Stater, 77054
- The University of Texas Health Science Center at Houston
-
-
Vermont
-
Bennington, Vermont, Forenede Stater, 05201
- Memory Clinic Inc
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22903
- University of Virginia
-
-
-
-
-
Bordeaux, Frankrig, 33076
- Hopital Pellegrin CHU Bordeaux
-
Lille, Frankrig, 59037
- Hopital Roger Salengro - CHU Lille
-
Nantes, Frankrig, 44093
- CHU Nantes - Hopital Nord Laënnec
-
Paris, Frankrig, 75010
- Hopital Lariboisiere-Fernand Widal
-
Paris, Frankrig, 75013
- Hopital Pitie Salpetriere
-
Rennes, Frankrig, 35009
- Chu Rennes Hopital Pontchaillou
-
Rouen, Frankrig, 76031
- Hopital Charles Nicolle
-
Toulouse, Frankrig, 31059
- CHU Toulouse - Hôpital La Grave
-
Tours, Frankrig, 37000
- Hôpital Bretonneau
-
-
-
-
-
's-Hertogenbosch, Holland, 5223 LA
- BRC - Den Bosch
-
Amsterdam, Holland, 1081 GN
- BRC - Amsterdam
-
Leeuwarden, Holland, 8934AD
- QPS Netherlands
-
Zwolle, Holland, 8052 AZ
- BRC Zwolle
-
-
-
-
-
Aizu-Wakamatsu, Japan, 965-8585
- Takeda General Hospital
-
Chiba, Japan, 263-0043
- Inage Neurology and Memory Clinic
-
Fujisawa-shi, Japan, 251-0038
- Kawashima Neurology Clinic
-
Fukuoka, Japan, 814-0180
- Fukuoka University Hospital
-
Hachiōji, Japan, 192-0071
- Keikokai P-One Clinic
-
Himeji, Japan, 672-8043
- Himeji Central Hospital Clinic
-
Kamakura-shi, Japan, 247-8533
- Shonan Kamakura General Hospital
-
Kanzaki-gun, Japan, 842-0192
- National Hospital Organization Hizen Psychiatric Center
-
Kawasaki, Japan, 210-0852
- Koukan Clinic
-
Kobe, Japan, 650-0047
- Kobe City Medical Center General Hospital
-
Kurashiki-shi, Japan, 7100813
- Rijikai Medical Corporation Katayama Medical Clinic
-
Kurume, Japan, 830-0011
- Kurume University Hospital
-
Kyoto, Japan, 607-8062
- Rakuwakai Otowa Hospital
-
Kyoto, Japan, 607-8113
- Rakuwakai Otowa Rehabilitation Hospital
-
Narashino, Japan, 275-0006
- Saiseikai Narashino Hospital
-
Obu-shi, Japan, 474-8511
- National Center For Geriatrics And Gerontology
-
Shinjuku-ku, Japan, 162-0053
- Clinical Research Hospital Tokyo
-
Tokyo, Japan, 160-0023
- Tokyo Medical University Hospital
-
Tokyo, Japan, 173-0015
- Tokyo Metropolitan Geriatric Hospital
-
Toyonaka-shi, Japan, 560-0004
- Nagomi Clinic
-
Toyonaka-shi, Japan, 5600004
- Jinsenkai MI Clinic
-
Yokohama, Japan, 235-0012
- Yokohama Brain and Spine Center
-
-
-
-
-
Algorta - Getxo, Spanien, 48993
- Centro At. Esp. Oroitu
-
Barcelona, Spanien, 08025
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, Spanien, 08003
- Hosp. Del Mar
-
Barcelona, Spanien, 08028
- Fund. Ace-Inst. Cat. Neuroc. Aplicades
-
Barcelona, Spanien, 08195
- Idc Salud Hosp. Gral. de Catalunya
-
Lleida, Spanien, 25198
- Hosp. Univ. Santa Maria
-
Madrid, Spanien, 28040
- Hosp. Clinico San Carlos
-
Terrassa, Spanien, 08221
- Hosp. Mutua Terrassa
-
Valencia, Spanien, 46026
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Stockholm, Sverige, 14186
- Karolinska Universitetssjukhuset
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Early Alzheimer's disease (AD): Gradual and progressive subjective decline in the participant's cognition over at least the past 6 months, as reported by the participant and informant (study partner) and Clinical Dementia Rating-Global Score (CDR-GS) of 0.5 and memory box score greater than or equal to (>=) 0.5 at screening
- Participants must have positive tau PET results
- Able to read and write and with a minimum 5 years of formal education as reported by participant and study partner at screening
- Have a designated study partner who has adequate literacy to participate and be judged to have high likelihood of completing the study with the participant
- Male participants must agree not to donate sperm for the purpose of reproduction during the study and up to 16 weeks after receiving the last dose of study intervention
Exclusion Criteria:
- Participants with CDR GS >=2 at predose baseline Clinical Dementia Rating (CDR) administration
- Participants who fulfill diagnostic criteria for Mild Cognitive Impairment (MCI) or dementia/mild or major neurocognitive disorder suspected to be due to any etiology other than AD (example, Parkinson's disease, cerebrovascular disease, normal pressure hydrocephalus, head injury, drug or alcohol abuse/dependence, anoxic brain injury, (Et cetera[etc])
- Geriatric Depression Scale (GDS) 30 score greater than (>) 12
- Hachinski Ischemic Scale (HIS) >4
- Has received medications that affect the central nervous system (CNS), except treatments for AD, for less than 2 months; that is, doses of chronic medications that effect the CNS should be stable for at least 2 months before the start of screening. If a participant has recently stopped a chronic medication that effects the CNS, he or she must have discontinued treatment at least 2 months before the start of screening. Chronic use of benzodiazepines is not permitted
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: JNJ-63733657 Low-dose
Participants will receive single dose of JNJ-63733657 low-dose administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period. Participants will have an option to continue with the long-term extension (LTE) phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period. |
JNJ-63733657 low or high dose will be administered by IV infusion. |
|
Eksperimentel: JNJ-63733657 High-dose
Participants will receive single dose of JNJ-63733657 high-dose administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will continue to receive the same treatment and dose during the LTE treatment period. |
JNJ-63733657 low or high dose will be administered by IV infusion. |
|
Placebo komparator: Placebo
Participants will receive single dose of matching placebo to JNJ-63733657 administered by IV infusion every 4 weeks during double-blind treatment period. Participants will have an option to continue with the LTE phase of the trial and will be re-randomized in a 1:1 ratio to receive either JNJ-63733657 low-dose or JNJ-63733657 high-dose during the LTE treatment period. |
Placebo matching to JNJ-63733657 will be administered by IV infusion. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Double-blind (DB) Treatment Period: Change From Baseline in Integrated Alzheimer's Disease Rating Scale for Mild Cognitive Impairment (iADRS-MCI) Total Score at Week 104
Tidsramme: Baseline (Day 1), Week 104
|
The iADRS-MCI was a composite measure of cognition and function. It was originally developed as a combination of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) 14-item cognition subscale and the instrumental activities of daily living (ADL) items from the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) scale. It was calculated as a linear combination of total scores of the 2 individual components. The iADRS-MCI total score was derived as a combination of the ADAS-Cog13 total score (ranging from 0 to 85, with higher scores indicating worse cognitive performance) and the ADCS-ADL-MCI total score (ranging from 0 to 53, with lower scores indicating worse daily function). Therefore, the iADRS-MCI total score was calculated as [-1(ADAS-Cog13 score)+85] + ADCS-ADL-MCI score, ranging from 0 to 138, with lower scores indicating worse performance. |
Baseline (Day 1), Week 104
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive, 13-item Version (ADAS-Cog13) Total Score at Week 104
Tidsramme: Baseline (Day 1), Week 104
|
The ADAS-Cog was a rater administered instrument that was designed to assess the severity of dysfunction in cognition characteristic of persons with Alzheimer's Disease (AD). The ADAS-Cog13 item scale includes all items from the original ADAS-Cog11 (consisting of 11 tasks measuring the disturbances of memory, language, praxis, attention, and other cognitive abilities, often referred to as the core symptoms of AD) in addition of number cancellation task and a delayed free recall task, for a total of 85 points (0 to 85), with higher scores indicating worse cognitive performance. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Alzheimer's Disease Cooperative Study Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI) Total Score at Week 104
Tidsramme: Baseline (Day 1), Week 104
|
The ADCS-ADL-MCI was a functional measure based on information provided by the study partner that describes the performance of participants in several activities of daily living. The ADCS-ADL-MCI scale consists of 17 instrumental items (example; shopping, preparing meals, using household appliances, etc) and 1 basic item (getting dressed). The ADCS-ADL-MCI scale version used in this study comprises 24 items of which 18 items are used for the standard analysis. The total score ranges from 0 to 53 with higher scores indicating less impairment. A positive change from baseline indicates healthy functioning while a negative change from baseline indicates a decline in independent functioning. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Index Score at Week 88
Tidsramme: Baseline (Day 1), Week 88
|
The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. The RBANS total scale Index score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160. Higher scores indicated better performance. |
Baseline (Day 1), Week 88
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 5 Individuals RBANS Indices at Week 88
Tidsramme: Baseline (Day 1), Week 88
|
The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning and story memory), visuospatial/constructional (figure copy and line orientation), language (picture naming and semantic fluency), attention (digit span and coding) and delayed memory (list recall, list recognition, story recall, and figure recall). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an standard deviation (SD) of 15. Sum of index scores was the sum of the 5 index scores, and the sum of index scores was converted to an RBANS total scale index score via a mapping table. The RBANS Total Scale Index Score was a norm-based t-score, based on a distribution with a mean of 100 and an SD of 15. Scores range from 40 to 160 each of the index scores. Higher scores indicated better performance. |
Baseline (Day 1), Week 88
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Each of the 12 Subtests Comprising the RBANS at Week 88
Tidsramme: Baseline (Day 1), Week 88
|
The RBANS was a battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that are divided into 5 RBANS indices: Immediate memory (list learning [0-40] and story memory [0-24]), visuospatial/constructional (figure copy [0-20] and line orientation [0-20]), language (picture naming [0-10] and semantic fluency [0-40]), attention (digit span [0-16] and coding [0-89]) and delayed memory (list recall [0-10], list recognition [0-20], story recall [0-12], and figure recall [0-20]). Index scores are expressed as an age-adjusted standard score with a normal mean of 100 and an SD of 15. Sum of index scores was the sum of the 5 index scores, and the Sum of Index Scores was converted to an RBANS total scale index score via a mapping table. Scores range from 40 to 160. Higher scores indicated better performance. |
Baseline (Day 1), Week 88
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-SB) Score at Week 104
Tidsramme: Baseline (Day 1), Week 104
|
The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: 1) memory, 2) orientation, 3) judgment and problem solving, 4) involvement in community affairs, 5) home and hobbies, and 6) personal care based on the CDR interview. The CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-SB was the sum of the 6 domains which ranged from 0 (least impairment) to 18 (severe impairment). Higher scores indicated worse disease state. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104
Tidsramme: Baseline (Day 1), Week 104
|
The NPI was a measure of psychobehavioral disturbances, assessing the frequency and severity of disturbances in 12 domains, based on a caregiver interview. For each domain, there was also an assessment of caregiver burden. Frequency for each domain was rated on a 4-point scale (from 1=rarely to 4=very often) and severity on a 3-point scale (from 1=mild to 3=severe), with the score for each domain being the product of the frequency and severity scores, such that each domain was scored from 1 to 12. The NPI total score was the sum of the 12 domain scores, ranged from 0 (best) to 144 (worst). Higher score indicated worst psychobehavior. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Percentage of Participants With Progression From Clinical Dementia Rating-Global Score (CDR-GS) 0 to 0.5 or Higher, 0.5 to 1 or Higher, and 1 to 2 or Higher
Tidsramme: From baseline (Day 1) up to Week 104
|
Percentage of participants with progression from CDR-GS 0 to 0.5 or higher, 0.5 to 1 or higher, and 1 to 2 or higher was reported. The CDR was a subjectively rated outcome measure that serves as a global clinical staging instrument. Six domains were assessed and then synthesized to assign a Global CDR score. It included 3 cognitive and 3 functional domains: (1) memory, (2) orientation, (3) judgment and problem solving, (4) involvement in community affairs, (5) home and hobbies, and (6) personal care based on the CDR interview. CDR was scored 2 ways yielding a global CDR score (CDR-GS and CDR-SB). CDR was an ordinal parameter (scale 0 [least impairment] to 3 [severe impairment]). The CDR-GS was derived based on an algorithm and was scored of 0 (normal), 0.5 (very mild dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). Score ranges from 0 to 3 and a high score on CDR-GS indicated a high disease severity. |
From baseline (Day 1) up to Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Brain Tau Burden as Measured by Tau Positron Emission Tomography (PET) at Week 104
Tidsramme: Baseline (Day 1), Week 104
|
Change from baseline in brain tau burden (tau naive composite Region of interest [ROI] standardized uptake value ratio [SUVR], cerebral cortex ROI SUVR, meta temporal ROI SUVR, spatial progression of tauopathy [SPOT] volume over cerebral cortex ROI) as measured by tau PET was reported. For tau naive ROI method, tau PET brain scans were assessed to measure change in SUVR over regions without evidence of tau burden at baseline (that is, within 1 standard deviation of a cognitively normal amyloid negative reference population). For SPOT method, tau PET brain scans were assessed to quantify extent of spread of tau by measuring difference in volume of elevated tau PET burden (defined as exceeding an SUVR threshold of 1.2) in cerebral cortex brain region at follow up versus that at baseline. Tau PET brain scans were assessed to measure spread of tau tangles using SUVR in cerebral cortex, meta temporal brain region, respectively. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Change From Baseline in Cerebrospinal Fluid (CSF) Concentrations of Total, Free, and Bound p217+Tau Fragments at Week 104
Tidsramme: Baseline (Day 1), Week 104
|
Change from baseline in CSF concentration of total, free, and bound p27+tau fragments at Week 104 was reported. |
Baseline (Day 1), Week 104
|
|
Double-blind (DB) Treatment Period: Cerebrospinal Fluid (CSF) Concentrations of JNJ-63733657
Tidsramme: Weeks 52, 104, and 208
|
CSF concentration of JNJ-63733657 was reported. |
Weeks 52, 104, and 208
|
|
Double-blind (DB) Treatment Period: Serum Concentrations of JNJ-63733657
Tidsramme: Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180
|
Serum concentration of JNJ-63733657 was reported. |
Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, 36, 52, 76, 104, 128, 156, and 180
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent JNJ-63733657 Antidrug Antibodies (ADAs) in Serum
Tidsramme: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent JNJ-63733657 ADA in serum was reported. Any ADAs occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. Participants with treatment-emergent antibodies to JNJ-63733657 included participants with treatment-induced antibodies to JNJ-63733657 and treatment-boosted antibodies to JNJ- 63733657. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Tidsramme: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Any AE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Tidsramme: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Serious adverse event (SAE) was any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Any SAE occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
Tidsramme: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent AESIs were collected in the eCRF and examined separately, grouped in the following categories including: hepatobiliary disorders/Liver enzyme abnormality, and Infusion-related reactions. Any AESI occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants Who Discontinued Study Treatment Due to AEs
Tidsramme: Baseline (Day 1) up to Week 232
|
Number of participants who discontinued the study treatment due to AE was reported. |
Baseline (Day 1) up to Week 232
|
|
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead Electrocardiogram (ECG) Parameter: ECG Mean Heart Rate Supine
Tidsramme: Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
Change from baseline in 12-lead ECG parameter (ECG mean heart rate supine) was reported. |
Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
|
Double-blind (DB) Treatment Period: Change From Baseline in 12-lead ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcB Interval, QTcF Interval, QTcL Interval, and RR Interval
Tidsramme: Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
Change from baseline in 12-lead ECG parameter (PR interval, QRS duration, QT interval, QTcB interval, QTcF interval, QTcL interval and RR interval) was reported. |
Baseline (Day 1), Weeks 4, 8, 12, 24, 36, 52, 76, 104, 128, 156, and 180
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormalities in Laboratory Parameters
Tidsramme: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent abnormalities in laboratory parameters (hematology, chemistry and urinalysis) were reported. Laboratory abnormalities meeting with lower limit of the normal range (LLN) and upper limit of the normal range (ULN) was reported. Any laboratory abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Neurological Examination
Tidsramme: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent abnormal findings in neurological examination (mental state, cranial nerves, motor ability: strength, tone, involuntary movements, coordination: finger-to-nose, gai, postural reflexes, sensation: proprioception, cold, light touch, deep tendon reflexes) was reported. Abnormalities in neurological examination was determined by the investigator. Any neurological abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Abnormal Findings in Physical Examination
Tidsramme: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent abnormal findings in physical examination (general appearance, skin, eye, ear, nose, throat, heart, head, neck, thyroid, chest, lung, abdomen, musculoskeletal, breast, neurological) was reported. Abnormal findings in physical examination was determined by the investigator. Any physical abnormalities occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Treatment-emergent Potentially Clinically Significant Vital Signs
Tidsramme: Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
Number of participants with treatment-emergent potentially clinically significant vital signs including systolic blood pressure (standing and supine: less than (<) 90 millimeters of mercury (mmHg) and greater than (>) 180 mmHg), diastolic blood pressure (standing and supine: <50 mmHg and >105 mmHg), pulse (<45 bpm to >120 bpm), temperature (<35 degree Celsius and >38 degree Celsius) and weight (decrease of >=10% relative to baseline and increase of >=10% relative to baseline) were reported. Any clinically significant vital sign occurring at or after the initial administration of study intervention through the day of last dose in the DB treatment period plus 90 days was considered to be treatment-emergent. |
Baseline (Day 1) up to 90 days after last dose of study intervention in DB period (Up to Week 245)
|
|
Double-blind (DB) Treatment Period: Number of Participants With Brain Magnetic Resonance Imaging (MRI) Safety Findings
Tidsramme: From Day 1 up to Week 245
|
Number of participants with brain MRI safety findings was reported. MRI safety-related observations from the central imaging vendor including vasogenic edema, cerebral macrohemorrhages, cerebral superficial siderosis and other findings was reported. |
From Day 1 up to Week 245
|
|
Double-blind (DB) Treatment Period: Number of Participants With Shift From Baseline in Suicidal Ideation or Suicidal Behavior as Assessed by Columbia Suicidality Severity Rating Scale (C-SSRS)
Tidsramme: Baseline (Day 1) up to Week 245
|
C-SSRS was a clinician-rated instrument that reports severity and frequency of suicide-related ideation and behaviors. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (non-specific active suicidal thoughts), 3 (suicidal ideation without plan and intent), 4 (suicidal ideation intent to act without plan), and 5 (suicidal ideation with plan and intent). Suicidal behavior was classified on a 5-item scale: 6 (preparatory acts or behavior), 7 (aborted attempt), 8 (interrupted attempt), 9 (actual attempt [non-fatal]), and 10 (suicide). Total score from 10 categories was summarized into 3 categories: No suicidal ideation or behavior(0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranged from 0 to 10. Higher scores indicated more severe suicidal ideation and behavior. |
Baseline (Day 1) up to Week 245
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CR108832
- 2020-000116-30 (EudraCT nummer)
- 63733657ALZ2002 (Anden identifikator: Janssen Research & Development, LLC)
- 2022-501188-42-00 (Registry Identifier: EUCT number)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .